[HTML][HTML] Recent advances in the applications of small molecules in the treatment of multiple myeloma
HN Abramson - International Journal of Molecular Sciences, 2023 - mdpi.com
Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …
First-line treatment of multiple myeloma in both transplant and non-transplant candidates
A Oriol, L Abril, G Ibarra - Expert Review of Anticancer Therapy, 2023 - Taylor & Francis
Introduction The last decade's progress in the treatment of newly diagnosed multiple
myeloma has relied on the synergistic combination of agents with different mechanisms of …
myeloma has relied on the synergistic combination of agents with different mechanisms of …
[HTML][HTML] The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer
B Tychhon, JC Allen, MA Gonzalez, IM Olivas… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Methods We used data from The Cancer Genome Atlas (TCGA) and the Clinical Proteomic
Tumor Analysis Consortium (CPTAC) available at UALCAN and/or GEPIA2 to assess the …
Tumor Analysis Consortium (CPTAC) available at UALCAN and/or GEPIA2 to assess the …
[HTML][HTML] Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
HK Lee, HY Jang, IW Kim, JM Oh - Journal of Cancer Research and …, 2024 - Springer
Purpose Carfilzomib, commonly used for relapsed/refractory multiple myeloma (RRMM), has
been associated with various adverse events in randomized controlled trials (RCTs) …
been associated with various adverse events in randomized controlled trials (RCTs) …
[HTML][HTML] Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center …
G Mingrone, A Astarita, A Colomba, C Catarinella… - Cancers, 2023 - mdpi.com
Simple Summary The use of carfilzomib in multiple myeloma is burdened by cardiovascular
toxicity. Currently, the risk stratification of cardiovascular adverse events appears well …
toxicity. Currently, the risk stratification of cardiovascular adverse events appears well …